tiprankstipranks
Trending News
More News >
Innovent Biologics (HK:1801)
:1801
Hong Kong Market

Innovent Biologics (1801) Financial Statements

Compare
22 Followers

Innovent Biologics Financial Overview

Innovent Biologics's market cap is currently $154.38B. The company's EPS TTM is HK$0.5701579323; its P/E ratio is 120.49; Innovent Biologics is scheduled to report earnings on August 27, 2025, and the estimated EPS forecast is HK$0.04. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 9.42B¥ 6.21B¥ 4.56B¥ 4.27B¥ 3.84B
Gross Profit¥ 7.91B¥ 4.40B¥ 3.63B¥ 3.70B¥ 3.46B
Operating Income¥ -755.87M¥ -1.68B¥ -3.12B¥ -2.70B¥ -557.18M
EBITDA¥ -480.28M¥ -660.68M¥ -1.75B¥ -2.37B¥ -704.74M
Net Income¥ -94.63M¥ -1.03B¥ -2.18B¥ -2.73B¥ -998.42M
Balance Sheet
Cash & Short-Term Investments¥ 7.88B¥ 10.97B¥ 9.17B¥ 9.02B¥ 8.12B
Total Assets¥ 21.60B¥ 20.63B¥ 17.59B¥ 16.24B¥ 11.83B
Total Debt¥ 2.83B¥ 3.62B¥ 3.23B¥ 2.50B¥ 1.21B
Net Debt¥ -4.68B¥ -6.43B¥ 2.21B¥ 1.14B¥ -69.61M
Total Liabilities¥ 8.48B¥ 8.10B¥ 6.86B¥ 5.91B¥ 3.06B
Stockholders' Equity¥ 13.12B¥ 12.53B¥ 10.73B¥ 10.33B¥ 8.78B
Cash Flow
Free Cash Flow¥ -418.39M¥ -1.24B¥ -3.30B¥ -3.87B¥ -1.08B
Operating Cash Flow¥ 1.29B¥ 147.81M¥ -1.92B¥ -2.02B¥ -307.69M
Investing Cash Flow¥ -1.17B¥ -998.66M¥ -1.44B¥ -2.70B¥ -5.18B
Financing Cash Flow¥ -606.63M¥ 2.59B¥ 2.89B¥ 5.00B¥ 4.91B
Currency in CNY

Innovent Biologics Earnings and Revenue History

Innovent Biologics Debt to Assets

Innovent Biologics Cash Flow

Innovent Biologics Forecast EPS vs Actual EPS